Eli Lilly and Company vs Walmart Inc.: Strategic Comparison

This in-depth comparison examines Eli Lilly and Company and Walmart Inc. across revenue, market value, business model, competitive positioning, and long-term growth strategy. Whether you are researching Eli Lilly and Company on its own, evaluating Walmart Inc., or weighing the two companies side by side, the breakdown below highlights where each company leads and where the gap between Eli Lilly and Company and Walmart Inc. is widest.

On the headline numbers, Eli Lilly and Company reports annual revenue of $65.2B against $713.2B for Walmart Inc., while their respective market capitalizations stand at $700.0B and $845.6B. Eli Lilly and Company is headquartered in United States and Walmart Inc. operates from United States, and those different home markets shape how each company competes.

Eli Lilly and Company: Revenue at Eli Lilly went from $28.5 billion in 2022 to $45 billion in 2024. That $16.5 billion increase in two years is not a corporate turnaround story — it's the commercial harvest of a single molecule: tirzepatide, sold as Mounjaro for diabetes and Zepbound for obesity. The drug became the fastest pharmaceutical product ever to reach $5 billion in annual sales, transforming a 148-year-old Midwestern company into one of America's most valuable corporations at a $700 billion market capitalization. The scientific lineage matters. Lilly produced the world's first commercially available insulin in 1923, giving type 1 diabetic patients who had previously faced certain death a reason to survive. That 1923 achievement planted the company in incretin biology — the study of gut hormones that regulate insulin secretion and appetite — where it would spend decades building intellectual and clinical depth. Tirzepatide is not a lucky discovery. It is the commercial output of that sustained investment. The SURMOUNT-5 trial made a specific claim that reshaped the competitive landscape: tirzepatide produced approximately 47% greater relative weight loss than semaglutide (Wegovy) in a direct head-to-head comparison. That's not a nuanced statistical edge — it's a clinically meaningful difference that gives physicians a reason to prescribe Zepbound over Novo Nordisk's product. The supply shortage that followed was the kind of problem that only hits companies whose demand has genuinely exceeded expectations. Retatrutide, Lilly's triple receptor agonist in Phase 3 development, showed average body weight reduction of approximately 24.2% over 48 weeks in a Phase 2 trial. If that number holds in Phase 3, it would represent the most effective pharmacological weight loss data ever published.

Walmart Inc.: Walmart generates $713.2 billion in annual revenue with a net margin around 3.1 percent — meaning roughly $22 billion falls to the bottom line from a business that employs 2.1 million people and operates stores in formats ranging from neighborhood markets to 180,000-square-foot Supercenters. The thin margin isn't a weakness; it's a deliberate pricing strategy that has destroyed competitors for six decades. The business is changing faster than the store count suggests. Advertising revenue, marketplace fees, membership income from Walmart+ and Sam's Club, and fulfillment services have added high-margin layers to a model that used to earn money only one way. These adjacent revenue streams don't show up obviously in a $713 billion revenue number, but they show up in margins. Sam Walton opened the first Walmart in Rogers, Arkansas in 1962. By 1970 the company went public. By 2000 it was the largest company in the world by revenue. The supply chain infrastructure built over those decades — cross-docking distribution centers, direct vendor relationships, proprietary logistics data — is what makes the everyday-low-price promise financially sustainable rather than merely aspirational. The Flipkart acquisition in 2018 gave Walmart a meaningful position in Indian e-commerce. The Jet.com acquisition in 2016 for $3.3 billion accelerated U.S. E-commerce capability. Neither produced the returns originally projected, but both shifted Walmart's trajectory in markets that would have been difficult to enter organically.

Eli Lilly and Company and Walmart Inc. pursue distinct approaches to generating revenue, and understanding how each company operates is the foundation of any fair comparison between Eli Lilly and Company and Walmart Inc..

Eli Lilly and Company business model: Lilly endured a lost decade marked by clinical failures in Alzheimer's disease research, insulin pricing controversies that drew congressional scrutiny, and generic competition that eroded blockbuster revenues. At its most fundamental level, Lilly's revenue model is straightforward: the company invests heavily in discovering and developing novel drugs, secures patent protection and regulatory approval for those drugs, manufactures them at scale, and sells them at premium prices to patients, healthcare systems, and payers. Insulin pricing has been a politically sensitive issue for Lilly, and in 2023 the company proactively announced it would cap monthly out-of-pocket costs for all insulin products at $35, a decision that absorbed short-term revenue impact but significantly reduced reputational and legislative risk. From a revenue geography perspective, the United States consistently represents the largest single market, accounting for approximately 65 percent of total revenues in 2024, reflecting both the premium pricing environment in American healthcare and the company's deep commercial infrastructure across hospitals, specialty pharmacies, and managed care organizations. The company's pricing and reimbursement strategy reflects the complex political economy of American pharmaceutical markets. Lilly's gross-to-net discount structure — the gap between list prices and the actual net prices after rebates, chargebacks, and discounts to payers and pharmacy benefit managers — has grown substantially as managed care organizations have exerted pricing pressure. Pricing and access policy represents a politically charged challenge with direct financial consequences. The Inflation Reduction Act of 2022 enable the Centers for Medicare and Medicaid Services to negotiate prices directly for high-expenditure drugs, and multiple Lilly products may become subject to negotiated pricing as the program expands in scope. The broader debate over pharmaceutical pricing, including congressional investigations and state-level legislative efforts, creates an ongoing environment of policy uncertainty that affects revenue planning and investor sentiment. Additionally, dozens of biotechnology companies and larger pharmaceutical corporations are developing oral GLP-1 agonists, next-generation dual and triple agonist molecules, and combination weight loss therapies that could fragment the market and compress Lilly's pricing power over the medium term.

Walmart Inc. business model: Walmart's revenue model is deceptively simple on the surface — buy stuff, sell stuff, repeat — but the economics underneath have shifted dramatically in the past five years. The company still makes most of its $713.2 billion from selling physical goods through physical stores. That hasn't changed. What's changed is what happens around those transactions. Start with the core: Walmart U.S. Generates roughly $460 billion in net sales annually. About 60% of that is grocery — milk, eggs, produce, frozen meals, cleaning supplies. The margins on grocery are thin, often below 20% gross. But grocery is the reason a family visits Walmart 4.2 times per month instead of once. Every trip past the produce aisle is a trip past pharmacy ($4 generics, vaccinations, health screenings), past general merchandise (where margins run 30-40%), past seasonal displays, past the impulse buys near checkout. Grocery is the loss leader that funds everything else. Sam's Club contributes approximately $90 billion through a different mechanism: membership fees. The $50-$110 annual fee from roughly 47 million members generates high-margin recurring revenue before a single item is scanned. The merchandise itself is sold at near-cost — the profit is in the membership, not the product. It's the Costco model, and Sam's Club has finally started executing it well after years of underperformance. Walmart International — about $120 billion — is a patchwork. Walmex in Mexico is a powerhouse, essentially the dominant retailer in the country. Canada is stable and profitable. China is complicated. India, through Flipkart and PhonePe, is a long-term bet on digital commerce in a market of 1.4 billion people where e-commerce penetration is still in single digits. Now here's where it gets interesting. Layered on top of the merchandise business are three high-margin revenue streams that barely existed five years ago: Walmart Connect — the advertising business — sells sponsored product placements, display ads, and now connected-TV inventory (via the VIZIO acquisition) to brands desperate to reach consumers at the moment of purchase. This business grew 37% in Q4 FY2026 and likely generates margins above 50%. For context: selling a $3 box of cereal might generate $0.15 in profit. Selling an ad to the cereal company that appears when a shopper searches "breakfast" on the Walmart app might generate $2-5 in pure margin. The math is significant. Walmart+ membership ($98/year) creates subscription revenue while locking in delivery habits. It's smaller than Amazon Prime — probably 20-30 million members versus Prime's 200+ million — but it's growing, and each member spends significantly more than non-members. Marketplace seller fees and Walmart Fulfillment Services generate commission and logistics revenue from third-party sellers who want access to Walmart's customer base without Walmart bearing inventory risk. The operating margins tell the real story: approximately 4-5% on $713 billion in revenue. That's about $28-35 billion in operating income. Sounds enormous until you realize that a 1% swing in gross margin — from a bad quarter of markdowns, or a spike in shrinkage, or a logistics cost overrun — wipes out $7 billion. The business runs on volume and velocity, not fat margins. Every efficiency gain matters. Every basis point of shrinkage reduction matters. That's why Walmart spends billions annually on supply chain automation, demand forecasting AI, and inventory management systems that most shoppers never see.

The durability of a company's moat often decides long-term winners. Here is how the competitive advantages of Eli Lilly and Company stack up against those of Walmart Inc..

Eli Lilly and Company competitive advantage: What makes Lilly's story particularly compelling is not just the scale of its recent success but the specific American geography it inhabits. The competitive landscape in which Eli Lilly operates has been radically reshaped over the past decade, both by the emergence of the GLP-1 drug class as a genuine blockbuster category and by the parallel evolution of oncology and immunology into scientifically sophisticated, targeted medicine domains where first-mover advantages and data depth matter enormously. Verzenio's revenue trajectory suggests it may eventually become the category leader despite entering the market after Ibrance, reflecting the value of superior clinical data over first-mover advantage in targeted oncology. The injectable nature of current tirzepatide formulations represents a patient acceptance barrier that, if removed through an effective oral alternative, would dramatically expand the addressable market. Eli Lilly's competitive advantages are rooted in four interconnected sources that, in combination, create a defensible position in the global pharmaceutical industry that goes beyond any single product success. This domain expertise is not merely historical; it manifests today in Lilly's pipeline of next-generation cardiometabolic molecules including orforglipron (an oral GLP-1 receptor agonist that could eliminate the injection barrier for millions of patients), retatrutide (a triple receptor agonist showing extraordinary weight loss results in Phase 2 trials — an average of 24.2 percent body weight reduction over 48 weeks), and other compounds targeting the intersection of metabolic disease, cardiovascular risk, and kidney function. Trust built through reliable insulin supply over a century translates into prescriber confidence in Lilly's newer products, creating a commercial starting advantage that newer entrants cannot replicate quickly. Fourth, Lilly's manufacturing infrastructure, while currently capacity-constrained, represents a long-term competitive moat. The technical complexity of sterile injectable biologics manufacturing creates meaningful barriers to generic and biosimilar entry, and the company's investments in dedicated tirzepatide manufacturing capacity will eventually provide scale advantages over potential competitors who face the same steep learning curves and capital requirements. By October 1923, Lilly was producing insulin on a commercial scale sufficient to supply diabetic patients across North America, and the company had developed an extract with substantially higher potency and reliability than earlier preparations.

Walmart Inc. competitive advantage: Consider what it would actually take to replicate Walmart's position from scratch. You'd need to acquire or build 4,700 stores positioned within ten miles of 90% of the U.S. Population — that's roughly $200 billion in real estate alone, assuming you could find the locations. You'd need relationships with tens of thousands of suppliers willing to give you their lowest wholesale prices — which they won't, because your volume doesn't justify it yet. You'd need a distribution network of 210+ facilities with a private fleet of 12,000+ trucks. You'd need 2.1 million trained employees. You'd need sixty years of brand recognition among American households. Nobody is doing that. Not Amazon, not Costco, not any private equity consortium. The physical infrastructure is the advantage, and it's essentially unreplicable at this point. But the more interesting defensive asset is behavioral. Walmart has embedded itself into the weekly routine of American households in a way that's almost invisible. People don't "decide" to shop at Walmart the way they decide to buy a new iPhone or subscribe to Netflix. They just. Go. It's Tuesday, the fridge is empty, the Walmart is seven minutes away. That habitual, low-consideration purchase behavior is extraordinarily sticky. It doesn't require brand love or emotional loyalty — it requires proximity and price, both of which Walmart dominates. The grocery frequency creates a data advantage that compounds over time. Walmart sees what 240 million people buy every week — not what they browse or click, but what they actually put in their cart and take home. That purchase data is gold for the advertising business, for demand forecasting, for private-label development, and for supplier negotiations. Amazon has browsing data and delivery data, but Walmart has in-store basket data at a scale nobody else touches. The store network also functions as a fulfillment advantage that pure e-commerce players can't match for perishable goods. You can't ship bananas from a centralized warehouse 800 miles away. You need local inventory, cold chain, and same-day capability. Walmart has all three, already built, already staffed, already stocked — in 4,700 locations. Amazon is spending billions trying to build grocery delivery infrastructure that Walmart inherited from decades of supercenter expansion.

Future prospects matter as much as current results. The growth strategies below explain how Eli Lilly and Company and Walmart Inc. each plan to expand from here.

Eli Lilly and Company growth strategy: That insulin partnership with the University of Toronto did not merely save lives; it established Lilly's identity as a science-first organization willing to pursue difficult biological problems across decades rather than quarters. Yet the company continued investing heavily in its research and development infrastructure, spending consistently between 20 and 25 percent of revenues on R&D even in lean years. Retevmo (selpercatinib), a RET kinase inhibitor for RET-altered cancers including certain lung and thyroid malignancies, and Jaypirca (pirtobrutinib), a BTK inhibitor for mantle cell lymphoma and chronic lymphocytic leukemia, represent Lilly's next-generation oncology assets with significant growth trajectories. Europe and Japan represent the next largest markets, with significant growth in emerging markets including China, where Lilly has maintained commercial operations for decades. This investment includes new sterile injectable fill-finish capacity and active pharmaceutical ingredient manufacturing to eliminate supply constraints that limited Zepbound and Mounjaro availability through much of 2023 and into 2024. The Indianapolis-based pharmaceutical company, which has survived Prohibition, the Great Depression, two World Wars, the AIDS crisis, multiple patent cliffs, and a decade of Alzheimer's drug failures, has in the early 2020s assembled what many analysts characterize as the most compelling pharmaceutical growth story of the current era. Ricks prioritized pipeline discipline over diversification, investing deeply in a small number of therapeutic areas where Lilly had genuine scientific depth rather than spreading resources thinly across many programs with mediocre differentiation. The company now invests more in R&D in absolute dollar terms than it generated in total revenues just fifteen years ago, illustrating both how dramatically the company has grown and how aggressively it is reinvesting to sustain that growth trajectory. For investors, healthcare professionals, policymakers, and patients, Lilly's evolution represents a case study in what pharmaceutical companies can achieve when long-term scientific commitment meets the right commercial moment. Lilly's competitive positioning in immunology is solid but not dominant, and the company's strategic priority is increasingly to defend existing Taltz revenues while investing in next-generation immunology candidates that could create new market leadership positions. This rate of growth is nearly unprecedented for a company of Lilly's scale in any industry, and it reflects almost entirely the commercial launch of tirzepatide across its Mounjaro and Zepbound indications. While Lilly's multi-billion-dollar manufacturing investment program is expected to alleviate these constraints by 2026 and 2027, the ramp-up period presents real financial and competitive risk, particularly as rival GLP-1 products from Novo Nordisk and potential new entrants compete for the same prescriber base and pharmacy shelf space. The irony is, Second, Lilly's brand equity among endocrinologists, cardiologists, and primary care physicians reflects decades of relationship-building through clinical education, medical affairs programs, and drug performance in real-world settings. Eli Lilly's growth strategy, as articulated through company investor presentations, earnings calls, and strategic communications under CEO David Ricks, rests on three interconnected pillars: maximizing the commercial potential of approved assets through indication expansion and market access improvement; sustaining pipeline productivity through disciplined internal R&D and targeted external business development; and building the manufacturing infrastructure necessary to support global demand at scale. The indication expansion strategy for tirzepatide is already well advanced. External business development has accelerated meaningfully under Ricks, reflecting a strategic recognition that internal R&D, while productive, cannot alone sustain the pipeline density required to replace revenue from products facing eventual patent expiry. Manufacturing investment represents the operational backbone of the growth strategy, with over $23 billion committed through 2027 to building capacity that will eliminate the supply constraints that have limited tirzepatide access and revenue since commercial launch. The trajectory of Eli Lilly over the next five to ten years is unusually legible by pharmaceutical industry standards, in large part because the company's near-term growth drivers are already approved and scaling and its longer-term pipeline candidates include multiple assets with multi-billion-dollar peak sales potential that have progressed to late-stage clinical development. Among the estimated 100 million Americans with obesity, fewer than 5 percent were receiving any pharmacological treatment as of 2024, suggesting an addressable population that could sustain revenue growth for many years even without new indications. New tirzepatide label expansions under investigation include heart failure with preserved ejection fraction (a trial already demonstrating positive results), sleep apnea, fatty liver disease (NASH/MASH), chronic kidney disease, and potentially cancer risk reduction. In Alzheimer's disease, donanemab (Kisunla) faces the challenge of building commercial infrastructure around a complex treatment model — patients require amyloid confirmation testing, infusion center visits, and MRI monitoring — but the underlying unmet medical need remains enormous, and Lilly is investing in diagnostic partnerships and infusion center networks to remove access barriers. The city was growing rapidly, positioned at the intersection of multiple rail lines that would increasingly define American commerce in the post-war era, and Lilly recognized both a business opportunity and a professional calling. He invested in analytical equipment to test raw materials before they entered production, a practice so unusual in the trade that it became a marketing point — Lilly medicines carried certificates of analysis years before regulatory bodies existed to require such documentation. This commitment to scientific integrity was not merely altruistic; it was a business strategy rooted in the belief that healthcare professionals, if given a choice, would prefer reliably effective medicines over cheaper alternatives that varied wildly in potency and purity. The company grew steadily through the late nineteenth century, expanding its product line from elixirs and tonics to a broader range of pharmaceuticals, moving into gelatin-coated capsules (a technology that significantly improved patient acceptance of medications) in the 1890s, and building a growing export business in Central and South America. The lesson of insulin — that patient, rigorous scientific investment in understanding complex biological mechanisms could produce far-reaching therapeutic outcomes — informed Lilly's research philosophy throughout the twentieth century and provides direct intellectual lineage to the GLP-1 and incretin research that would eventually produce tirzepatide seven decades later.

Walmart Inc. growth strategy: Walmart's growth bet is straightforward, even if the execution is brutally complex: use the weekly grocery trip as a platform to sell higher-margin services. Advertising is the crown jewel. Walmart Connect grew 37% in Q4 FY2026, and management has signaled this is still early innings. The logic is compelling — brands have always paid for shelf placement in physical stores (those end-cap displays aren't free), and now they'll pay for digital shelf placement too. The VIZIO acquisition in 2024 added connected-TV advertising to the mix, meaning Walmart can now sell ads that follow a shopper from their living room TV to the Walmart app to the in-store digital display. That closed-loop attribution is what advertisers crave, and it's something only retailers with massive first-party purchase data can offer. Marketplace expansion is the volume play. Walmart.com now hosts hundreds of thousands of third-party sellers, dramatically expanding the product catalog without requiring Walmart to buy or warehouse inventory. Each seller pays referral fees (typically 6-15%), and many pay for Walmart Fulfillment Services and Walmart Connect ads on top of that. The flywheel is obvious: more sellers means more selection, which means more shoppers, which attracts more sellers. Automation is the cost play. Online grocery delivery is currently unprofitable at scale — the labor cost of picking, packing, and delivering a $120 grocery order eats the margin entirely. Walmart is investing heavily in automated micro-fulfillment centers inside existing stores, where robots pick ambient and refrigerated items while human associates handle produce and fragile goods. The goal is to cut the cost-per-order for e-commerce fulfillment by 30-50% over the next three years. The international portfolio is selective. Flipkart in India is the big swing — a market where 900 million people will come online as shoppers over the next decade. Walmex in Mexico is the steady compounder. Everything else is either stable (Canada) or being managed for returns rather than growth (China, Chile). Notably absent from this strategy: dramatic store expansion in the U.S. Walmart isn't building hundreds of new supercenters. The 4,700 existing U.S. Stores are the infrastructure. The strategy is to extract more revenue and profit per square foot from what already exists.

A closer look at the financial trajectory of Eli Lilly and Company and Walmart Inc. rounds out the comparison.

Eli Lilly and Company: $9.3 billion spent on research and development in fiscal year 2024 — a number that exceeds Lilly's entire revenue base in 2009. That reinvestment rate, sustained over years, is the financial explanation for tirzepatide's commercial performance. Drugs of this clinical quality don't emerge from modest R&D budgets. Net income reached $10.59 billion in FY2025 on $65.2B in revenue, a 23.5% net margin that reflects the pricing power of a drug that genuinely outperforms its competition. The revenue trajectory has been steep: $28.3 billion in 2021, $28.5 billion in 2022, $34.1 billion in 2023, $65.2B in FY2025. Each year's jump is larger than the last, driven by tirzepatide's expansion across indications and geographies. The supply shortage controversy in 2023 had a real financial component. Manufacturing capacity for GLP-1 drugs requires specialized equipment and long lead times. Lilly has committed billions in capital expenditure to expand manufacturing — but the gap between demand and supply means some prescription revenue is being left on the table during a period when competitive dynamics are most favorable. The Loxo Oncology acquisition in 2019 cost approximately $8 billion. The oncology pipeline it delivered — including selpercatinib and other targeted therapies — now contributes revenue that diversifies Lilly's earnings away from the GLP-1 concentration risk. Market capitalization of $700 billion prices in continued GLP-1 dominance and successful Phase 3 outcomes for retatrutide. Either of those assumptions failing would reprice the stock significantly.

Walmart Inc.: Revenue grew from $611.3 billion in fiscal 2023 to $713.2 billion in fiscal 2026, a pace that represents roughly $100 billion in additional annual revenue over three years — a figure larger than most Fortune 500 companies' total revenues. Grocery volume, U.S. E-commerce growth, Sam's Club membership expansion, and the international segment all contributed. The $845.6 billion market capitalization against $713.2 billion in revenue implies a price-to-sales multiple above one — a premium to what a pure grocer would command, reflecting the market pricing in the advertising, marketplace, and membership businesses as higher-multiple growth assets embedded inside the retail operation. The net income figure is not separately disclosed in the available data, but at a 3.1 percent margin on $713.2 billion, the implied earnings are substantial in absolute terms while modest as a percentage. That combination — large absolute earnings, thin margins — is exactly the arithmetic that makes Walmart's competitive position so durable. Matching its pricing requires matching its cost structure, which requires matching its volume, which is circular. Advertising revenue is the financial development worth watching closely over the next decade. Walmart Connect, the advertising platform, operates at margins that bear no resemblance to retail. Every transaction in every store and on Walmart.com generates data about what customers buy, when, and at what price — data that consumer goods companies will pay significant fees to target precisely.